RxDoctor Payments Data

Carolyn Zawislak, PA

Physician Assistant · Philadelphia, PANPI 1952776908

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $23,000 of the $29,170 with a category attached, or 78.8%. AstraZeneca accounts for 80.2% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $17,308 and has fallen 79.3% since, to $3,587 in 2025. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,170in general payments, 2019–2025

Across 90 payments — averaging $324.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$23K
  • Merck$3K
  • Eisai Inc.$801
  • Pfizer$720
  • Bayer$285
  • E.r. Squibb & Sons, L.L.C.$208
  • plus $358 from 3 others

What the payments were for

  • Consulting fees$1,4185%
  • Speaking & faculty fees$23,00079%
  • Travel & lodging$1,7856%
  • Food & beverage$2,86810%
  • Education$990%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,170 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,405
Medicare patients
55
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$28,758
XareltoRivaroxaban13$9,574
Ondansetron Hcl148$1,805
Dexamethasone65$1,024
Olanzapine90$1,010
Bupropion Hcl SrBupropion Hcl20$733
Albuterol Sulfate HfaAlbuterol Sulfate20$568
Celecoxib26$455
Prednisone59$406
Hydrocortisone26$388
Morphine Sulfate ErMorphine Sulfate21$350
Levothyroxine Sodium48$315
Lidocaine-PrilocaineLidocaine/Prilocaine18$232
Mirtazapine11$214
Oxycodone Hcl24$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$720$28,75844 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →